Farmacokinetics and farmacodynamics of drugs used in neonates and children during Extracorporal Membanous Oxygenation (ECMO)

Farmacokinetics and farmacodynamics of drugs used in neonates and children during Extracorporal Membanous Oxygenation (ECMO) - farmacotherapy during ECMO

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON30690

Enrollment

100

Registered

2007-02-09

Start date

2007-02-15

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patienten aan ECMO heart-lung machine

Interventions

None listed

Eligibility

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: neonates and children 0-18 year on ECMO

Exclusion criteria

Exclusion criteria: Witheld informed consent

Design outcomes

Primary

Measure	Time frame
Karacterizing the Pharmacokinetics of different drugs (analgesia, sedatives, antibiotics, inotropic agents, PGE5 inhibitor, and diuretics) routinely used in patients undergoing ECMO. Describing the relationship between pharmacokinetics and demografical, physiological, pathophysiological factors like diagnosis, genotype, PRISM/PIM scores, liver and kidney function albumin concentrations, different ECMO modi, ECMO flow, dialysis, bloodtransfusions and ventilator settings.	—

Measure

Time frame

Karacterizing the Pharmacokinetics of different drugs (analgesia, sedatives, antibiotics, inotropic agents, PGE5 inhibitor, and diuretics) routinely used in patients undergoing ECMO. Describing the relationship between pharmacokinetics and demografical, physiological, pathophysiological factors like diagnosis, genotype, PRISM/PIM scores, liver and kidney function albumin concentrations, different ECMO modi, ECMO flow, dialysis, bloodtransfusions and ventilator settings.

—

Secondary

Measure	Time frame
Karacterizing the relationship between pharmacokinetics and clinical effects of the above mentioned medication. Describing the relationship between pharmacodynamics and demografical, physiological, pathophysiological factors. Formulating dosing regimes for the studied medication for patients treated with ECMO.	—

Countries

Netherlands

Outcome results